Trial Profile
A 24-Week, Multi-Centre, International, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Phase III Study With a 78-Week Extension Period to Evaluate the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycaemic Control on Metformin Alone
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Dec 2021
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Obesity; Overweight; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors AstraZeneca
- 20 Apr 2020 Results (n=7005) of pooled analysis of 13 phase II/III trials: MB102008, MB102013, MB102014, MB102028, MB102029, MB102030, MB102032, MB102033, MB102034, MB102047, MB102061, MB102067, MB102080 were published in the British Journal of Clinical Pharmacology
- 23 Jan 2018 Results (n=220) of pooled analysis of 11 phase 3 trial assessing effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and stages 3b-4 chronic kidney disease, were published in the Nephrology Dialysis Transplantation.
- 01 Nov 2016 Results of a pooled post-hoc analysis of five phase IIb and 16 phase III studies (including this study) assessing frequency and characteristics of hypersensitivity adverse events, published in the Clinical Drug Investigation.